Login / Signup

Preclinical mouse models for immunotherapeutic and non-immunotherapeutic drug development for pancreatic ductal adenocarcinoma.

Mengni HeMacKenzie HendersonStephen MuthAdrian MurphyLei Zheng
Published in: Annals of pancreatic cancer (2020)
Pancreatic ductal adenocarcinoma (PDAC) is in urgent need of better diagnostic and therapeutic methods due to its late diagnosis, limited treatment options and poor prognosis. Finding the right animal models to recapitulate the tumor molecular pathogenesis and tumor microenvironment (TME) complexity is critical for preclinical immunotherapeutic and non-immunotherapeutic treatment developments. In this review, we summarize and evaluate popular preclinical animal models including patient-derived xenograft models, humanized mouse models, genetically engineered mouse models, and syngeneic mouse models. Through comparisons between these models in different research settings, we hope to provide guidance in finding the most relevant preclinical models to suit various research purposes.
Keyphrases
  • mouse model
  • poor prognosis
  • cell therapy
  • long non coding rna
  • stem cells
  • bone marrow
  • monoclonal antibody
  • single molecule
  • combination therapy
  • smoking cessation